Biotech, RNA Interference, Duchenne Muscular Dystrophy
AVI Gets $3M For Muscular Dystrophy
Luke Timmerman 6/4/09
AVI Biopharma (NASDAQ:AVII), the Portland, OR-based developer of RNA-based therapies, said today it will receive another $3 million from Charley’s Fund to further develop an experimental drug for Duchenne Muscular Dystrophy. AVI’s contract with the foundation is now worth a total of $5 million to develop AVI-5038, with a goal of taking the drug into clinical trials. This is AVI’s second drug candidate against Duchenne Muscular Dystrophy, and is designed to affect a different genetic variation than the first, the company said.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
